Bioavailability of PRUVIN® and Its Effects in Healthy Subjects (INDIGO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-01

Study Completion Date

2020-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of different doses of PRUVIN® (N-acetylcysteine \[NAC\] and glycine) on reduced glutathione levels in healthy elderly subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating a Natural Antioxidant Food Product on Oxidative Stress in Recreationally Active Participants

NCT04959006

Oxidative Stress Exercise Recovery

COMPLETED NA

Effects of PRJ-205 on Performance in Trained Young Subjects

NCT02726516

Healthy

COMPLETED NA

The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance

NCT01244360

Inflammation

UNKNOWN NA

Ischemia Reperfusion: Prostaglandins and Antioxidants

NCT01666587

Ischemic Reperfusion Injury

COMPLETED NA

Effect of Resveratrol Supplementation on Exercise Performance and Recovery

NCT06723119

Effect of Resveratrol on Performance and Recovery

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center, double-blind, randomized, placebo-controlled 4-arm study-design, to assess the safety, tolerability and effect of PRUVIN® on reduced glutathione levels in healthy elderly (age 60-85 years) subjects.

In addition, baseline values of glutathione precursors, glutathione, and plasma markers of oxidative stress in a healthy young cohort (non-interventional) will be compared with those of the healthy elderly cohort (interventional).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oxidative Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blind, randomized, Placebo-controlled

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)

* First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning
* Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening

Group Type ACTIVE_COMPARATOR

Pruvin R

Intervention Type DIETARY_SUPPLEMENT

Combination of N-acetylcysteine an glycine

4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)

* First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning
* Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening

Group Type ACTIVE_COMPARATOR

Pruvin R

Intervention Type DIETARY_SUPPLEMENT

Combination of N-acetylcysteine an glycine

2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)

* First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning
* Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening

Group Type ACTIVE_COMPARATOR

Pruvin R

Intervention Type DIETARY_SUPPLEMENT

Combination of N-acetylcysteine an glycine

Placebo control (7.2 g isomaltulose)(arm D)

* First dose (3.6 g isomaltulose) consumed in the morning
* Second dose (3.6 g isomaltulose) taken in the evening

Group Type PLACEBO_COMPARATOR

Isomaltulose

Intervention Type OTHER

Placebo as comparator to intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pruvin R

Combination of N-acetylcysteine an glycine

Intervention Type DIETARY_SUPPLEMENT

Isomaltulose

Placebo as comparator to intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 20-40 years, both inclusive
2. male and female
3. Considered generally healthy upon completion of medical history and screening safety assessments, as judged by the Investigator.
4. BMI \>18.5 and \<30.0 kg/m2
5. HbA1c \<5.7 %
6. Informed consent as documented by signature

1. 60-85 years, both inclusive
2. male and female
3. Sedentary, less than 1h of strenuous physical exercise per week
4. BMI of 25.0 to 35.0 kg/m2, both inclusive
5. HbA1c\<6.5 %
6. Informed consent as documented by signature

Exclusion Criteria

1. Receipt of any medicinal product or nutritional product in clinical development within 30 days before enrollment in this trial.
2. Any history or presence of clinically relevant comorbidity, as judged by the Investigator.
3. Signs of acute illness as judged by the Investigator.
4. Any serious systemic infectious disease during four weeks prior enrollment in this trial
5. Clinically significant abnormal screening laboratory tests, as judged by the Investigator.
6. AST and/or ALT \> 2 times the upper limit of normal.
7. Elevated serum creatinine values above the upper limit of normal.
8. Systolic blood pressure \< 90 mmHg or \>139 mmHg and/or diastolic blood pressure \< 50 mmHg or \>89 mmHg (excluding white-coat hypertension; therefore, a repeat test showing results within range will be acceptable).
9. Heart rate at rest outside the range of 50-90 beats per minute.
10. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.
11. Significant history of alcoholism or drug abuse as judged by the Investigator consuming more than 24 grams alcohol/day (for males), 12 grams alcohol/day (for females) on average.
12. Smoking or use of nicotine substitute products.
13. Any medication (prescription and non-prescription drugs) within 14 days before screening.
14. Blood donation or blood loss of more than 500 mL within the last 3 months prior to screening.
15. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
16. If female, pregnant or breast-feeding.
17. Consumption of high protein supplements within 60 days of screening and during the study.
18. Consumption of any antioxidant, vitamins, and herbals (see chapter 12.2) supplements within 2 weeks prior to screening and during the study.

Interventional Cohort:

1. Known or suspected hypersensitivity to any component of the trial products.
2. Receipt of any medicinal product or nutritional product in clinical development within 30 days before randomisation in this trial.
3. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
4. Any history or presence of clinically relevant comorbidity, as judged by the Investigator.
5. Signs of acute illness as judged by the Investigator.
6. Any serious systemic infectious disease during four weeks prior to first intake of the trial product, as judged by the Investigator.
7. Clinically significant abnormal screening laboratory tests, as judged by the Investigator.
8. AST and/or ALT \> 2 times the upper limit of normal.
9. Elevated serum creatinine values above the upper limit of normal.
10. Systolic blood pressure \< 90 mmHg or \>139 mmHg and/or diastolic blood pressure \< 50 mmHg or \>89 mmHg (excluding white-coat hypertension; therefore, a repeat test showing results within range will be acceptable).
11. Heart rate at rest outside the range of 50-90 beats per minute.
12. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.
13. Significant history of alcoholism or drug abuse as judged by the Investigator consuming more than 24 grams alcohol/day (for males), 12 grams alcohol/day (for females) on average.
14. Smoking more than 5 cigarettes or the equivalent per day.
15. Inability or unwillingness to refrain from smoking and use of nicotine substitute products 3 days prior and during the intervention.

Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes